1. Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on interferon plus ribavirin.
- Author
-
Sánchez-Conde M, Gil P, Sánchez-Somolinos M, Gonzalez-Lahoz J, and Soriano V
- Subjects
- Adenine adverse effects, Adenine therapeutic use, Anti-HIV Agents adverse effects, Antiretroviral Therapy, Highly Active, Antiviral Agents therapeutic use, Female, HIV, HIV Infections complications, Hepacivirus genetics, Hepatitis C complications, Humans, Interferon alpha-2, Male, Organophosphonates therapeutic use, RNA, Viral blood, Recombinant Proteins, Tenofovir, Adenine analogs & derivatives, HIV Infections drug therapy, Hepatitis C drug therapy, Interferon-alpha therapeutic use, Kidney drug effects, Liver drug effects, Organophosphonates adverse effects, Polyethylene Glycols therapeutic use, Ribavirin therapeutic use
- Abstract
The liver safety of tenofovir (TDF) was investigated in 142 HIV+ patients exposed to the drug for longer than 12 months. No evidence of liver enzyme elevations were seen, even in 66 patients with chronic hepatitis C virus (HCV) co-infection. Given that TDF is an adenosine analogue, like didanosine, exposure to ribavirin might increase intracellular phosphorylated TDF metabolites, which could result in a higher risk of nephrotoxicity. Signs of tubular dysfunction in blood or urine were not recognized in 17 HCV-HIV co-infected patients exposed to TDF during interferon plus ribavirin therapy.
- Published
- 2005
- Full Text
- View/download PDF